Clinical Trials Logo

Clinical Trial Summary

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.


Clinical Trial Description

In this phase II trial, the investigators evaluate the efficacy and safety of S-588410 containing oncoantigens-derived HLA-A*2402-restricted epitope peptides in patients with HLA-A*2402 who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02410369
Study type Interventional
Source Tokyo University
Contact Yataro Daigo, MD, PhD
Phone 03-5449-8111
Email dctsm@ims.u-tokyo.ac.jp
Status Recruiting
Phase Phase 2
Start date March 2015
Completion date September 2021